Biopool International gains approval for five more reagents:
This article was originally published in Clinica
Five chemistry reagent systems developed by Biopool International have been approved for marketing in the US. The five reagents - blood urea nitrogen, creatine kinase, alanine aminotransferase, lactate dehydrogenase and triglycerides - together with the lipase reagent approved last year form the beginning of a panel of 15 tests Biopool plans to develop over the next year. The clinical chemistry reagents will compete in a market estimated at $2,000 million.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.